ASC30 Completes First Dosing in US Phase II Clinical Trial for Diabetes Treatment
January 26, 2026
Source: drugdu
49
On January 26, Ascletis Pharma (01672) announced that it had completed dosing of the first subjects in its Phase II US study of the oral small molecule GLP-1R agonist ASC30 for the treatment of diabetes. Top-line data from the study are expected to be available in the third quarter of 2026.
A 13-week study in obese or overweight subjects showed that ASC30 resulted in a placebo-adjusted weight loss of up to 7.7%, with better gastrointestinal tolerability and no liver safety signals observed. The study enrolled 125 obese subjects or overweight subjects with at least one weight-related comorbidity.
At the primary endpoint of week 13, once-daily doses of ASC30 tablets at 20 mg, 40 mg, and 60 mg resulted in weight loss of 5.4%, 7.0%, and 7.7%, respectively, which were statistically significant and clinically meaningful. The overall discontinuation rate due to adverse events was 4.8%.
ASC30 is the first small molecule GLP-1R fully biased agonist currently in clinical trials, and is indicated for the treatment of obesity, diabetes and other metabolic diseases.
https://finance.eastmoney.com/a/202601263630078795.html
By editor
Copyright©2026 Ddu. All rights reserved.
Read more on
- Rising Star in Oral Weight Loss! Hengrui’s GLP 1R/GIPR Agonist Succeeds in Phase II Study February 13, 2026
- adjuvant therapy for breast cancer February 13, 2026
- The approval of telpopril monotherapy for type 2 diabetes has driven an upgrade in the management paradigm February 13, 2026
- Oral insulin launch fails; China Resources Pharmaceutical plans to sell Tianmai Biotechnology February 13, 2026
- Hanyu Pharmaceutical’s glatiramer acetate injection receives FDA approval in the United States. February 13, 2026
your submission has already been received.
OK
Subscribe
Please enter a valid Email address！
Submit
The most relevant industry news & insight will be sent to you every two weeks.
